Page last updated: 2024-10-24

verapamil and Degenerative Diseases, Central Nervous System

verapamil has been researched along with Degenerative Diseases, Central Nervous System in 4 studies

Verapamil: A calcium channel blocker that is a class IV anti-arrhythmia agent.
verapamil : A racemate comprising equimolar amounts of dexverapamil and (S)-verapamil. An L-type calcium channel blocker of the phenylalkylamine class, it is used (particularly as the hydrochloride salt) in the treatment of hypertension, angina pectoris and cardiac arrhythmia, and as a preventive medication for migraine.
2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile : A tertiary amino compound that is 3,4-dimethoxyphenylethylamine in which the hydrogens attached to the nitrogen are replaced by a methyl group and a 4-cyano-4-(3,4-dimethoxyphenyl)-5-methylhexyl group.

Research Excerpts

ExcerptRelevanceReference
" The CCBs nimodipine (NDP) and verapamil (VPM) both significantly suppressed toxic secretions from human astrocytes and astrocytoma U-373 MG cells that were induced by interferon (IFN)-γ."1.38Inhibition of human astrocyte and microglia neurotoxicity by calcium channel blockers. ( Hashioka, S; Klegeris, A; McGeer, PL, 2012)

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (50.00)29.6817
2010's2 (50.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Bartels, AL1
de Klerk, OL1
Kortekaas, R1
de Vries, JJ1
Leenders, KL1
Hashioka, S1
Klegeris, A1
McGeer, PL1
Sarang, SS1
Yoshida, T1
Cadet, R1
Valeras, AS1
Jensen, RV1
Gullans, SR1
Doyle, KM1
Kirby, BP1
Murphy, D1
Shaw, GG1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Randomized Double Blind Placebo Controlled Trial of Verapamil in Chronic Rhinosinusitis[NCT02454608]29 participants (Actual)Interventional2015-05-31Terminated (stopped due to Evidence that the dose is insufficient.)
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Diastolic Blood Pressure

(NCT02454608)
Timeframe: Mean change between baseline and week 8 measurements

InterventionmmHg (Mean)
Treatment-0.6
Control1

Heart Rate

(NCT02454608)
Timeframe: Mean change between baseline and week 8 measurements.

Interventionbeats per minute (Mean)
Treatment-1.4
Control4

Objective Sinonasal Symptoms on Lund-Kennedy Score(LKS)

Minimum Score: 0 Maximum Score: 12 Higher value represents worse outcome. (NCT02454608)
Timeframe: baseline to week 8

Interventionunits on a scale (Least Squares Mean)
Treatment-1.3
Control-0.25

Objective Sinonasal Symptoms on Lund-McKay Score(LMS)

Minimum Score: 0 Maximum Score: 24 Higher value represents worse outcome. (NCT02454608)
Timeframe: Week 8

Interventionunits on a scale (Mean)
Treatment12.5
Control17.7

Subjective Sinonasal Symptoms on 10cm Visual Analogue Scale(VAS)

Minimum Score: 0 Maximum Score: 100 A higher score indicates a worse outcome. (NCT02454608)
Timeframe: baseline to week 8

Interventionunits on a scale (Least Squares Mean)
Treatment-44.03
Control-6.07

Subjective Sinonasal Symptoms on Sinonasal Outcomes Test-22(SNOT-22)

Minimum Score: 0 Maximum Score: 110 A higher score indicates a worse outcome (NCT02454608)
Timeframe: baseline to week 8

Interventionunits on a scale (Least Squares Mean)
Treatment-27.3
Control0.4

Systolic Blood Pressure

(NCT02454608)
Timeframe: Mean change between baseline and week 8 measurements

InterventionmmHg (Mean)
Treatment-4.5
Control-6.6

Subjective Sinonasal Symptoms on 10cm Visual Analogue Scale(VAS)

Minimum Score: 0 Maximum Score: 100 A higher score indicates a worse outcome. (NCT02454608)
Timeframe: baseline to week 56

Interventionunits on a scale (Mean)
Medicine Completers, baselineMedicine Completers, week 56Surgical Completers, baselineSurgical Completers, week 12
Open Label64.335.090.016.7

Subjective Sinonasal Symptoms on Sinonasal Outcomes Test-22(SNOT-22)

Minimum Score: 0 Maximum Score: 110 A higher score indicates a worse outcome (NCT02454608)
Timeframe: baseline to week 56

Interventionunits on a scale (Mean)
Medicine Completers, baselineMedicine Completers, week 56Surgical Completers, baselineSurgical Completers, week 12
Open Label31.824.1472.008.00

Reviews

1 review available for verapamil and Degenerative Diseases, Central Nervous System

ArticleYear
11C-verapamil to assess P-gp function in human brain during aging, depression and neurodegenerative disease.
    Current topics in medicinal chemistry, 2010, Volume: 10, Issue:17

    Topics: Aging; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blood-Brain Barrier; Brain Diseases;

2010

Other Studies

3 other studies available for verapamil and Degenerative Diseases, Central Nervous System

ArticleYear
Inhibition of human astrocyte and microglia neurotoxicity by calcium channel blockers.
    Neuropharmacology, 2012, Volume: 63, Issue:4

    Topics: Astrocytes; Calcium Channel Blockers; Calcium Channels, L-Type; Cell Line; Cells, Cultured; Chemokin

2012
Discovery of molecular mechanisms of neuroprotection using cell-based bioassays and oligonucleotide arrays.
    Physiological genomics, 2002, Oct-29, Volume: 11, Issue:2

    Topics: Biological Assay; Drug Evaluation, Preclinical; Gene Expression Profiling; Gene Expression Regulatio

2002
Effect of L-type calcium channel antagonists on spermine-induced CNS excitation in vivo.
    Neuroscience letters, 2005, Jun-03, Volume: 380, Issue:3

    Topics: Amines; Animals; Calcium Channel Blockers; Calcium Channels, L-Type; Central Nervous System; Convuls

2005